Jennifer Kayden Lee Sells 4,189 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee sold 4,189 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $58.91, for a total transaction of $246,773.99. Following the sale, the executive vice president now owns 4,409 shares of the company’s stock, valued at approximately $259,734.19. The trade was a 48.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jennifer Kayden Lee also recently made the following trade(s):

• On Tuesday, February 4th, Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $59.43, for a total value of $85,995.21.

Rhythm Pharmaceuticals Trading Up 0.1 %

Shares of RYTM opened at $57.64 on Thursday. Rhythm Pharmaceuticals, Inc. has a 1-year low of $35.17 and a 1-year high of $68.58. The firm’s 50-day moving average price is $57.11 and its 200-day moving average price is $53.51. The firm has a market capitalization of $3.54 billion, a price-to-earnings ratio of -13.31 and a beta of 2.14.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. TD Cowen raised their price target on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. JMP Securities restated a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Canaccord Genuity Group reiterated a “buy” rating and set a $80.00 price target on shares of Rhythm Pharmaceuticals in a report on Tuesday, November 19th. Guggenheim started coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 21st. They set a “buy” rating and a $70.00 price target for the company. Finally, Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 price objective on the stock. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $68.09.

Institutional Trading of Rhythm Pharmaceuticals

Several large investors have recently bought and sold shares of the company. SRS Capital Advisors Inc. raised its position in shares of Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after acquiring an additional 400 shares in the last quarter. Raleigh Capital Management Inc. purchased a new stake in Rhythm Pharmaceuticals in the fourth quarter worth $28,000. SBI Securities Co. Ltd. bought a new position in Rhythm Pharmaceuticals in the fourth quarter worth $37,000. R Squared Ltd purchased a new position in Rhythm Pharmaceuticals during the fourth quarter valued at $44,000. Finally, ORG Wealth Partners LLC bought a new stake in shares of Rhythm Pharmaceuticals during the 3rd quarter valued at $63,000.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.